Is actemra effective for giant cell arteritis?

What symptoms improve with Actemra for giant cell arteritis?

Actemra reduces sustained remission rates in giant cell arteritis patients compared with placebo. It also lowers the number of patients needing glucocorticoids, glucocorticoid dose exposure, and time to flare. [1]

Why are companies challenging this patent?

No companies are currently challenging the Actemra patent for giant cell arteritis. The manufacturer holds active patents covering the use of tocilizumab in giant cell arteritis until at link [2]

Can biosimilars enter before patent expiry?

Biosimilars for tocilizumab will likely enter the market after patent expiry. Current data shows no active biosimilar challenges or launches for the giant cell arteritis indication. [3]

What side effects are patients asking about?

Patients report infection risk, elevated liver enzymes, and gastrointestinal perforations as concerns with Actemra use. These are listed in the official prescribing information.